Literature DB >> 20078618

Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients.

Olivier Mir, Bernadette Dessard-Diana, Agnès Lillo-Le Louet, Pierre Loulergue, Jean-Paul Viard, Anne Langlois, Catherine Durdux, Christine Le Beller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20078618      PMCID： PMC2830603          DOI： 10.1111/j.1365-2125.2009.03555.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

1.  Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.

Authors:  Heleen A Bardelmeijer; Mariët Ouwehand; Tessa Buckle; Maarten T Huisman; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

2.  Proposal for a new tool to evaluate drug interaction cases.

Authors:  John R Horn; Philip D Hansten; Lingtak-Neander Chan
Journal:  Ann Pharmacother       Date:  2007-03-27       Impact factor: 3.154

3.  Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma.

Authors:  Pierre Loulergue; Olivier Mir; Jérôme Allali; Jean-Paul Viard
Journal:  AIDS       Date:  2008-06-19       Impact factor: 4.177

4.  Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.

Authors:  J Alexandre; E Rey; V Girre; S Grabar; A Tran; V Montheil; F Rabillon; V Dieras; V Jullien; P Hérait; G Pons; J-M Treluyer; F Goldwasser
Journal:  Ann Oncol       Date:  2006-10-23       Impact factor: 32.976

Review 5.  Clinical pharmacokinetics of docetaxel.

Authors:  S J Clarke; L P Rivory
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

Review 6.  Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

Authors:  Robert K Zeldin; Richard A Petruschke
Journal:  J Antimicrob Chemother       Date:  2003-12-04       Impact factor: 5.790

7.  Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma.

Authors:  Denise Bundow; David M Aboulafia
Journal:  Am J Clin Oncol       Date:  2004-02       Impact factor: 2.339

8.  A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.

Authors:  Wei-Peng Yong; Ling-Zhi Wang; Lai-San Tham; Chiung-Ing Wong; Soo-Chin Lee; Ross Soo; Norita Sukri; How-Sung Lee; Boon-Cher Goh
Journal:  Cancer Chemother Pharmacol       Date:  2007-10-02       Impact factor: 3.333

9.  Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation.

Authors:  T Cresteil; B Monsarrat; P Alvinerie; J M Tréluyer; I Vieira; M Wright
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

10.  Clinical pharmacodynamic factors in docetaxel toxicity.

Authors:  F Puisset; J Alexandre; J-M Treluyer; V Raoul; H Roché; F Goldwasser; E Chatelut
Journal:  Br J Cancer       Date:  2007-06-26       Impact factor: 7.640
View more
  6 in total

Review 1.  Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

Authors:  Michelle A Rudek; Charles Flexner; Richard F Ambinder
Journal:  Lancet Oncol       Date:  2011-05-12       Impact factor: 41.316

2.  Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs.

Authors:  Alice Tseng; Michelle Foisy
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

3.  Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.

Authors:  Michelle A Rudek; Cathy Y Chang; Kenneth Steadman; Michael D Johnson; Naveen Desai; John F Deeken
Journal:  Cancer Chemother Pharmacol       Date:  2014-02-02       Impact factor: 3.333

4.  Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.

Authors:  Pierre Loulergue; Mansouria Merad; Romain Coriat; Michel Ducreux; David Planchard; Valérie Boige; Axel Le Cesne; Thomas M Gregory; Vianney Poinsignon; Angelo Paci; Olivier Mir
Journal:  Invest New Drugs       Date:  2016-11-12       Impact factor: 3.850

Review 5.  Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer.

Authors:  Neus Basté Rotllan
Journal:  Cancer Med       Date:  2022-10       Impact factor: 4.711

6.  P-glycoprotein- and organic anion-transporting polypeptide-mediated transport of periplocin may lead to drug-herb/drug-drug interactions.

Authors:  Sheng Liang; Fengchun Deng; Haiyan Xing; He Wen; Xiaoyan Shi; Orleans Nii Martey; Emmanuel Koomson; Xin He
Journal:  Drug Des Devel Ther       Date:  2014-05-09       Impact factor: 4.162
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.